Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2702135 | 1.00 | LMNA (0.57) | LMNAALDH1A1THRB | |
| Tetrahydrofuran SCHEMBL2260480 | 0.98 | LMNA (0.60) | LMNAALDH1A1THRB | |
| Tetrahydrofuran SCHEMBL9877354 | 0.98 | LMNA (0.60) | LMNAALDH1A1THRB | |
| Dioxane SCHEMBL7672675 | 0.87 | LMNA (0.67) | LMNAALDH1A1THRB | |
| Cyclopropane SCHEMBL1406305 | 0.84 | LMNA (0.80) | LMNATHRB | |
| SCHEMBL7847095 | 0.84 | LMNA (0.80) | LMNATHRB | |
| SCHEMBL767256 | 0.84 | LMNA (0.55) | LMNATHRB | |
| Tetrahydrofuran SCHEMBL9464976 | 0.83 | ALDH1A1 (0.40) | LMNAALDH1A1THRB | |
| Tetrahydrofuran SCHEMBL9148484 | 0.82 | LMNA (0.43) | LMNA | |
| Tetrahydrofuran SCHEMBL10505828 | 0.80 | THRB (0.58) | LMNAALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051336-B2 | Regioselective acylation of rapamycin at the C-42 position | SANDOZ (CH) | 2015-06-09 | — | — | US | claimed |
| US-20140081016-A1 | REGIOSELECTIVE ACYLATION OF RAPAMYCIN AT THE C-42 POSITION | SANDOZ AG (CH) | 2014-03-20 | — | — | US | claimed |
| CN-116601163-A | Protected disaccharides, methods for their preparation, their use in the synthesis of zwitterionic oligosaccharides and conjugates thereof | 巴斯德研究所 | 2023-08-15 | — | — | CN | disclosed |
| CN-115485267-A | Synthesis of vinylcyclobutyl intermediates | 安进公司 | 2022-12-16 | — | — | CN | disclosed |
| CN-115485269-A | Ring-closure synthesis of macrocyclic MCL-1 inhibitor intermediates | 安进公司 | 2022-12-16 | — | — | CN | disclosed |
| CN-115485268-A | Synthesis of vinyl protected alcohol intermediates | 安进公司 | 2022-12-16 | — | — | CN | disclosed |
| US-6800618-B2 | PHENOTHIAZINE OR IMINODIBENZYL DERIVATIVES AS ANTIMALARIAL AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2004-10-05 | — | — | US | disclosed |
| US-20030032801-A1 | Chemosensitizing agents against chloroquine resistant plasmodium falciparum and methods of making and using thereof | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2003-02-13 | — | — | US | disclosed |
| WO-2002089810-A1 | CHEMOSENSITIZING AGENTS AGAINST CHLOROQUINE RESISTANT PLASMODIUM FALCIPARUM AND METHODS OF MAKING AND USING THEREOF | UNITED STATES ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032801-A1 | Chemosensitizing agents against chloroquine resistant plasmodium falciparum and methods of making and using thereof | ABCC1, SLC11A2, G6PD | LMNA 3498/4885ALDH1A1 1368/4885THRB 4043/4885 |
| US-20140081016-A1 | REGIOSELECTIVE ACYLATION OF RAPAMYCIN AT THE C-42 POSITION | RICTOR, RPTOR, MTOR | LMNA 3230/4885ALDH1A1 4526/4885THRB 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.